Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Adaptive Biotechnologies CorpADPT-4.755.493.37-5.58-66.76%-20.29%47.64$5.61$11.9326,227$6.29

Detail of Adaptive Biotechnologies Corp

 
CEO
Mr. Chad M. Robins M.B.A, M.B.A.
Employees
858
Industry
Biotechnology
Sector
Healthcare
Market cap
$927M

Company details

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
NI
Revenue (Rev)
$168.77M
Cost of goods (CoG)
-$76.33M
Gross profit (GP)
$92.44M
Operating expense (OE)
-$276.20M
Research and development (R&D)
-$112.88M
General and administrative (G&A)
-$163.32M
Operating income (OI)
-$185.47M
Other income expense (OIE)
-$7.20M
Pretax income (PI)
-$213.57M
Net income (NI)
-$213.57M
Adaptive Biotechnologies Corp
ADPT • XNGS • US
$6.29
+1.11 (21.43%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$1.33
Margin profit
-110.13%
52 week low
$2.34
52 week high
$7.0665
50-day simple moving average
$5.68
200-day simple moving average
$5.61
Percent held by insiders
1.93%
Percent held by institutions
93.97%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ADPT +29.16%
eps change
ADPT 0.00%